CD40L-HVEM DCR

CD40L-HVEM DCR is a synthetic fusion protein, specifically a Dual Costimulatory Receptor (DCR), developed for use in engineered T-cell therapies to treat acute myeloid leukemia (AML). The construct consists of the extracellular domain of CD40 ligand (CD40L) fused to the intracellular costimulatory signaling domain of the Herpesvirus Entry Mediator (HVEM). When expressed on the surface of T cells, the CD40L ectodomain binds to CD40 on macrophages and other myeloid cells within the tumor microenvironment, promoting their conversion from a pro-tumorigenic (M2) to an anti-tumorigenic (M1) phenotype. Simultaneously, the HVEM endodomain provides a potent costimulatory signal to the engineered T cell itself, enhancing its activation, proliferation, and cytotoxic activity against AML cells. This dual-action mechanism aims to harness both innate and adaptive immunity to overcome the immunosuppressive environment of the bone marrow in AML patients.

Other names

CD40L-HVEM Dual Costimulatory ReceptorCD-40L-HVEM Dual Costimulatory ReceptorCD 40L-HVEM Dual Costimulatory Receptor